Dawn Furey

Dawn’s storied career of landmark achievements in drug development at both Merck and Janssen, the pharmaceutical arm of Johnson & Johnson, including her operational leadership within Operation Warp Speed on behalf of Johnson & Johnson to develop their COVID-19 vaccine and enroll 45,000 patients within 8 weeks, her executive success in implementing disruptive, transformational processes within clinical development to accelerate study start-up times, predictably enroll clinical trial patients, and drive diversity within participants – seen throughout the Merck & Janssen portfolios, and her breakthrough leadership in the expansion of clinical research throughout Eastern Europe and Russia, optimizing the footprint of trials in underutilized geographies and expanding access to clinical trials as a care option.